EE537 Cost-Effectiveness of Cemiplimab in Patients With Advanced Basal Cell Carcinoma (aBCC) Who Progressed on or Are Intolerant to a Hedgehog Inhibitor (HHI) in Italy
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.778
https://www.valueinhealthjournal.com/article/S1098-3015(22)02982-5/fulltext
Title :
EE537 Cost-Effectiveness of Cemiplimab in Patients With Advanced Basal Cell Carcinoma (aBCC) Who Progressed on or Are Intolerant to a Hedgehog Inhibitor (HHI) in Italy
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02982-5&doi=10.1016/j.jval.2022.09.778
First page :
Section Title :
Open access? :
No
Section Order :
10320